Portada›Lunes 26 de octubre de 2026

Biomédicas del NASDAQ ante la SEC, lunes 26 de octubre de 2026

Los 39 documentos que 37 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← viernes 23 de octubre de 2026

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Emisiones y dilución

1. ABOSAcumen Pharmaceuticals, Inc.S-3Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …2025, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note 1 to the financial statements), included therein, and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon such report…
2. TRAWTraws Pharma, Inc.S-1Capacidad de emisión registradaEDGAR

   El informe de auditoría sobre los estados financieros consolidados de 31 de diciembre de 2025 incluye un párrafo que indica pérdidas recurrentes desde el inicio y dudas sustanciales sobre la continuidad de la empresa.

   Original en inglés · traducción automática

   covering the December 31, 2025 consolidated financial statements contains an explanatory paragraph that states that the Company has incurred recurring losses from operations since inception that raise substantial doubt about the entity’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.

   Traducción automática (claude-sonnet-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

3. GRMLGreenland Mines LtdS-1Capacidad de emisión registradaEDGAR
4. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
5. PULMPulmatrix, Inc.424B3Prospecto suplementario o de reventaEDGAR

   El prospecto se refiere a la reventa por el accionista vendedor de hasta 491.607 acciones ordinarias, emitibles por conversión de acciones preferentes Series B Convertible Preferred Stock y como dividendos.

   Original en inglés · traducción automática

   resale by the selling stockholder named in this prospectus from time to time of up to an aggregate of 491,607 shares of our common stock, par value $0.0001 per share (the “Common Stock”), issuable upon (i) the conversion of shares of our newly designated Series B Convertible Preferred Stock (the “Preferred Shares”) and (ii) the issuance of Common Stock as dividends to the holders of the Preferred Shares (the “Dividend Shares”).

   Traducción automática (claude-sonnet-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

6. TRAXFirst Tracks Biotherapeutics, Inc.S-1Capacidad de emisión registradaEDGAR

Participaciones y control

1. CTYCITY THERAPEUTICS, INC.SC 13DCambio en participación significativaEDGAR
2. IRONDisc Medicine, Inc.SC 13D/ACambio en participación significativaEDGAR
3. LONALeonaBio, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. EQEquillium, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
2. LGVNLongeveron Inc.8-KOtros hechos relevantesEDGAR
   En el documentoEl ensayo NO alcanzó su objetivo principaltexto original ▸

   …Significance ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions ● As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data ● Additional analysis demonstrates an important pre-specified secondary…

   En el documentoDesignación de medicamento huérfanotexto original ▸

   …encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit…
3. ONCOOnconetix, Inc.8-KOtros hechos relevantesEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …Exhibit 99.1 Onconetix Announces Reverse Stock Split CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company’s common stock has been assigned a new CUSIP number…
4. ORKAOruka Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
   En el documentoEl ensayo alcanzó su objetivo principaltexto original ▸

   …increased in a dose-dependent manner across ORKA-001 treatment groups, with the high-dose (600 mg) group outperforming both lower dose groups on complete skin clearance. 61% of patients in the high-dose group achieved the primary endpoint of PASI 100 at Week 16, compared to 0% of patients receiving placebo (p<0.0001). The ORKA-001 high-dose group demonstrated high response rates across secondary endpoints, including 86% of patients achieving…
5. SNTISenti Biosciences Holdings, Inc.8-KFin de acuerdo materialEDGAR

   Los accionistas aprobaron una reverse stock split de las acciones ordinarias con una proporción de entre 1 por 20 y 1 por 50, a determinar por el consejo.

   Original en inglés · traducción automática

   stockholders approved a reverse stock split of the Company’s common stock at a ratio within the range of 1-for-20 to 1-for-50, as determined by the board of directors. The reverse stock split remains subject to the Company’s board determining to implement the reverse stock split and is not reflected in the pro forma adjustments included in Note 2 below.

   Traducción automática (claude-sonnet-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

6. SUPNSUPERNUS PHARMACEUTICALS, INC.8-KFin de acuerdo materialEDGAR
7. ABOSAcumen Pharmaceuticals, Inc.8-KResultadosEDGAR
   En el documentoDesignación de vía rápida (Fast Track)texto original ▸

   …soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD. About ALTITUDE-AD (Phase 2) Initiated in 2024, ALTITUDE…
8. ABOSAcumen Pharmaceuticals, Inc.10-QInforme trimestralEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …ongoing clinical trial and other research and development expenses, and the Company cannot predict the amount or timing of all expenditures with certainty. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern. The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course…
9. APVOAptevo Therapeutics Inc.8-KOtros hechos relevantesEDGAR

   Mipletamig ha recibido la designación de medicamento huérfano para la AML con arreglo a la Orphan Drug Act.

   Original en inglés · traducción automática

   Mipletamig has received orphan drug designation for AML under the Orphan Drug Act. In the solid tumor space, Aptevo's lead assets are focused on well-established targets to progress novel immunomodulatory platform backbones that are conditionally active only in the tumor.

   Traducción automática (claude-sonnet-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

10. AVBPArriVent BioPharma, Inc.8-KOtros hechos relevantesEDGAR
11. CLYMClimb Bio, Inc.8-KOtros hechos relevantesEDGAR
    En el documentoDesignación de medicamento huérfanotexto original ▸

    …clinical trials for pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). A subcutaneous formulation is also in development to enable broader patient access. Budoprutug has been granted Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of pMN. Forward-Looking Statements This press release contains “forward-looking statements” including, without limitation, statements regarding…

    En el documentoDesignación de vía rápida (Fast Track)texto original ▸

    …clinical trials for pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). A subcutaneous formulation is also in development to enable broader patient access. Budoprutug has been granted Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of pMN. Forward-Looking Statements This press release contains “forward-looking statements” including, without limitation, statements regarding: future expectations, plans…
12. CPIXCUMBERLAND PHARMACEUTICALS INC8-KOtros hechos relevantesEDGAR
    En el documentoDesignación de medicamento huérfanotexto original ▸

    …requested in the pre-NDA meeting. Ifetroban is a once-daily oral medication that works by blocking the thromboxane-prostanoid receptor, which plays a key role in inflammation and fibrosis. The drug has received Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation from the FDA for the indication of cardiomyopathy associated with DMD. Long-term safety data from the ongoing open-label extension support…

    En el documentoDesignación de vía rápida (Fast Track)texto original ▸

    …requested in the pre-NDA meeting. Ifetroban is a once-daily oral medication that works by blocking the thromboxane-prostanoid receptor, which plays a key role in inflammation and fibrosis. The drug has received Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation from the FDA for the indication of cardiomyopathy associated with DMD. Long-term safety data from the ongoing open-label extension support the tolerability of ifetroban in DMD. Through up to 36 months…
13. CTORCITIUS ONCOLOGY, INC.8-KResultadosEDGAR
14. CTXRCitius Pharmaceuticals, Inc.8-KResultadosEDGAR
15. EIKNEikon Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
16. JAZZJazz Pharmaceuticals plc8-KResultadosEDGAR
17. LYCALycia Therapeutics, Inc.8-KCambio de estatutosEDGAR
18. MCRBSeres Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸

    …Certain Officers; Compensatory Arrangements of Certain Officers. On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the “Company”), resigned from her positions as Executive Vice President and Chief Financial Officer of the Company, effective November 15, 2026 (the “Effective Date”). Following the Effective Date, Ms. Thorell is expected to provide advisory services to the Company to support an orderly transition,…
19. MIRMMirum Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
20. NEOGNEOGEN CORP8-K/ACambio en el consejo o la direcciónEDGAR
21. PHATPhathom Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
22. RLYBRallybio Corp8-KOtros hechos relevantesEDGAR
23. SLXNSilexion Therapeutics Corp8-KCambio de estatutosEDGAR
24. VBIOValion Bio, Inc.8-KOtros hechos relevantesEDGAR
25. XBITXBiotech Inc.8-KCambio en el consejo o la direcciónEDGAR
26. XNCRXencor Inc8-KResultadosEDGAR

Juntas de accionistas

1. GLSIGreenwich LifeSciences, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
2. TCRXTScan Therapeutics, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR

   La compañía informa de que el 27 de agosto de 2026 recibió de Nasdaq una carta de incumplimiento relacionada con el precio de cierre de su acción durante los 30 días de negociación consecutivos anteriores a la carta.

   Original en inglés · traducción automática

   on August 27, 2026, the Company received a deficiency letter (the “Nasdaq Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Nasdaq Letter, the closing bid price of the Company’s voting common stock had not been maintained at the minimum required closing bid price of at least $1.00 per share, as required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”).

   Traducción automática (claude-sonnet-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

3. TPSTTempest Therapeutics, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …Share numbers included in the following tables and footnotes in this Executive and Director Compensation section have been adjusted, as necessary, for the 1-for-13 reverse stock split of our common stock effected on April 8, 2025 (the “Reverse Stock Split”). Summary Compensation Table The following table sets forth information for each of the last two completed fiscal years regarding compensation awarded to or earned by our Former Chief Executive Officer…
4. ZYMEZymeworks Inc.DEF 14AConvocatoria de junta de accionistasEDGAR

← viernes 23 de octubre de 2026

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.